Analysis of Newly Expanded Cumulative Cohort Demonstrates that DecisionDx-Melanoma Improves Risk Prediction for Patients with Cutaneous Melanoma

50

FRIENDSWOOD, Texas–(BUSINESS WIRE)–Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of newly expanded performance results for DecisionDx®-Melanoma at the 2019 Fall Clinical Dermatology Conference for PAs & NPs held in Scottsdale, Arizona. The poster, titled “The prognostic 31-gene expression profile (31-GEP) test improves risk prediction in cutaneous melanoma (CM)….

 

 

 

 

http://www.businesswire.com/news/home/20190606005168/en/Analysis-Newly-Expanded-Cumulative-Cohort-Demonstrates-DecisionDx-Melanoma